Navigation Links
Jennerex Closes $5 Million First Tranche of Series C Financing
Date:8/11/2009

SAN FRANCISCO, Aug. 11 /PRNewswire/ --Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biopharmaceutical company developing a proprietary breakthrough class of targeted oncolytic virus therapeutics, today announced the first closing of a private placement financing with gross proceeds of US $5,123,521, exceeding the target of $5 million USD. A second closing is anticipated on or before September 15, 2009, with additional proceeds to be determined.

The net proceeds of the private placement will be used to continue advancing the Company's clinical development programs with the lead product JX-594. Key value creating trials include the following: initiation of a randomized Phase 3 liver cancer trial, completion of a Phase 2 colon cancer trial and a Phase 1 trial targeting lung cancer and other solid tumors. Proceeds will also be used for research and development, general corporate purposes and to augment working capital.

"We are again delighted by the enthusiastic support of existing shareholders, and also welcome several new shareholders to the Company," said David H. Kirn, M.D., President and CEO. "This funding, together with cash resources on hand, is expected to cover operations for the next 16 months, through the end of 2010, and specifically to fund the company through significant value inflection points, including completion of the above-mentioned Phase 1 and Phase 2 clinical trials," said Dr. Kirn.

About Jennerex

Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594, currently in an international Phase 2 trial for primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common large market cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the Company's poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this mechanism of action and the results in patients to date put the Company's product class in a leadership position. Jennerex Biotherapeutics was established in San Francisco and in Ottawa in 2006 with Dr. David Kirn (CEO) in San Francisco and Dr. John Bell (CSO) from the Ottawa Hospital Research Institute/University of Ottawa. For more information about Jennerex and the Company's robust pipeline of three clinical-stage products, please visit www.jennerex.com .


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
2. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
3. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
4. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
5. Micromet Closes $80.5 Million Public Offering of Common Stock
6. PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants
7. Signostics Closes Follow-On Financing of US$4 Million, Expands Board of Directors
8. NewLink Genetics Corporation Closes $7.5 Million Financing
9. Pharmaxis Closes Share Purchase Plan
10. China Biologic Products Closes the $9.6 Million Private Placement
11. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- Regular discussions on a range of subjects including policies, debt ... said Poloz. Speaking at a lecture to the ... pointed to the country,s inflation target, which is set by ... "In certain areas there needs to ... goals, why not sit down and address strategy together?" ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking ... Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity as ...
Breaking Biology Technology:
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
Breaking Biology News(10 mins):